Bristol-Myers Squibb has succeeded in its pursuit of Amylin Pharmaceuticals by agreeing to acquire the company in a deal valued at approximately US$7 B, including US$1.7 B towards the settlement of Amylin’s net debt and a contractual payment obligation to Eli Lilly. In an interesting twist, upon closing of the transaction AstraZeneca will pay approximately US$3.4 B in cash in order to become a development and commercialisation partner for Amylin’s product portfolio with equal sharing of profits and losses.